Benzodiazepines for prolonged seizures

Archives of Disease in Childhood: Education and Practice Edition

Volumn 95, Issue 6, 2010, Pages 183-189

  Anderson, Mark ^a  

^a Infectious Diseases Allergy   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIAZEPAM; LORAZEPAM; MIDAZOLAM; PARALDEHYDE;

AMNESIA; CONFUSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; EPILEPTIC STATE; HANGOVER; HUMAN; NONHUMAN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SINGLE DRUG DOSE;

ANTICONVULSANTS; BENZODIAZEPINES; CHILD, PRESCHOOL; DIAZEPAM; HUMANS; INFANT; LORAZEPAM; MIDAZOLAM; STATUS EPILEPTICUS;

EID: 78649844541     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/adc.2009.176321     Document Type: Review

References (67)

1. International League Against Epilepsy Commission on Epidemiology and Prognosis. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34:592-6.
2. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the defi nition of status epilepticus. Epilepsia 1999;40:120-2. (Pubitemid 29031765)
3. Shinnar S, Hesdorffer DC, Nordli DR Jr, et al. Phenomenology of prolonged febrile seizures: results of the FEBSTAT study. Neurology 2008;71:170-6.
4. Raspall-Chaure M, Chin RF, Neville BG, et al. Outcome of paediatric convulsive status epilepticus: a systematic review. Lancet Neurol 2006;5:769-79. (Pubitemid 44209399)
5. Lombroso CT. Intermittent home treatment of status and clusters of seizures. Epilepsia 1989;30(Suppl 2):S11-14.
6. Shader RJ, Greeblatt DJ. Benzodiazepines: some aspects of their clinical pharmacology. Ciba Found Symp 1979;74:141-55.
7. Sieghart W, Fuchs K, Tretter V, et al. Structure and subunit composition of GABA(A) receptors. Neurochem Int 1999;34:379-85. (Pubitemid 29240634)
8. McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 1996;19:139-43.
9. Campo-Soria C, Chang Y, Weiss DS. Mechanism of action of benzodiazepines on GABAA receptors. Br J Pharmacol 2006;148:984-90. (Pubitemid 44543616)
10. Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 1999;6:69-83.
11. Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J Pediatr Gastroenterol Nutr 2008;47:3-10.
12. Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol 2008:335-60.
13. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002;43(Suppl 3):53-9.
14. Arnold J. Determinants of pharmacologic effects and toxicity of benzodiazepine hypnotics: role of lipophilicity and plasma elimination rates. J Clin Psychiatry 1991;52(Suppl):11-14.
15. Leppik IE, Derivan AT, Homan RW, et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983;249:1452-4.
16. Galvin GM, Jelinek GA. Midazolam: an effective intravenous agent for seizure control. Arch Emerg Med 1987;4:169-72.
17. Ferngren HG. Diazepam treatment for acute convulsions in children. A report of 41 patients, three with plasma levels. Epilepsia 1974;15:27-37.
18. Remy C, Jourdil N, Villemain D, et al. Intrarectal diazepam in epileptic adults. Epilepsia 1992;33:353-8.
19. Walker JE, Homan RW, Crawford IL. Lorazepam: a controlled trial in patients with intractable partial complex seizures. Epilepsia 1984;25:464-6.
20. Goodkin HP, Kapur J. The impact of diazepam's discovery on the treatment and understanding of status epilepticus. Epilepsia 2009;50:2011-18.
21. Ikumi ML, Muchohi SN, Ohuma EO, et al. Response to diazepam in children with malaria-induced seizures. Epilepsy Res 2008;82:215-18.
22. Lackner TE. Strategies for optimizing antiepileptic drug therapy in elderly people. Pharmacotherapy 2002;22:329-64.
23. Cock HR, Schapira AH. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM 2002;95:225-31.
24. Hayashi K, Osawa M, Aihara M, et al. Effi cacy of intravenous midazolam for status epilepticus in childhood. Pediatr Neurol 2007;36:366-72. (Pubitemid 46873924)
25. Chin RF, Neville BG, Peckham C, et al. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008;7:696-703.
26. Appleton R, Sweeney A, Choonara I, et al. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 1995;37:682-8.
27. Chiulli DA, Terndrup TE, Kanter RK. The infl uence of diazepam or lorazepam on the frequency of endotracheal intubation in childhood status epilepticus. J Emerg Med 1991;9:13-17.
28. Giang DW, McBride MC. Lorazepam versus diazepam for the treatment of status epilepticus. Pediatr Neurol 1988;4:358-61.
29. Appleton R, Choonara I, Martland T, et al. The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party. Arch Dis Child 2000;83:415-19.
30. Qureshi A, Wassmer E, Davies P, et al. Comparative audit of intravenous lorazepam and diazepam in the emergency treatment of convulsive status epilepticus in children. Seizure 2002;11:141-4. (Pubitemid 34693042)
31. Fisgin T, Gurer Y, Teziç T, et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol 2002;17:123-6. (Pubitemid 34498440)
32. Scott RC, Besag FM, Boyd SG, et al. Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics. Epilepsia 1998;39:290-4.
33. Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol 2006;34:355-9.
34. Graves NM, Kriel RL, Jones-Saete C. Bioavailability of rectally administered lorazepam. Clin Neuropharmacol 1987;10:555-9.
35. Malinovsky JM, Lejus C, Servin F, et al. Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. Br J Anaesth 1993;70:617-20.
36. Saint-Maurice C, Meistelman C, Rey E, et al. The pharmacokinetics of rectal midazolam for premedication in children. Anesthesiology 1986;65:536-8.
37. Gizurarson S, Gudbrandsson FK, Jónsson H, et al. Intranasal administration of diazepam aiming at the treatment of acute seizures: clinical trials in healthy volunteers. Biol Pharm Bull 1999;22:425-7.
38. Ahmad S, Ellis JC, Kamwendo H, et al. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. Lancet 2006;367:1591-7.
39. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav 2004;5:253-5.
40. Lahat E, Goldman M, Barr J, et al. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ 2000;321:83-6.
41. Scott RC, Besag FM, Neville BG. Intranasal midazolam for treating febrile seizures in children. Buccal midazolam should be preferred to nasal midazolam. BMJ 2001;322:107.
42. Huyton M, Mair K, Hindley D. Audit of the use of buccal diazepam at a residential centre for children with epilepsy. Dev Med Child Neurol 2007;49:160.
43. Muchohi SN, Kokwaro GO, Ogutu BR, et al. Pharmacokinetics and clinical effi cacy of midazolam in children with severe malaria and convulsions. Br J Clin Pharmacol 2008;66:529-38.
44. Mpimbaza A, Ndeezi G, Staedke S, et al. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics 2008;121:e58-64.
45. McIntyre J, Robertson S, Norris E, et al. Safety and effi cacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005;366:205-10.
46. Greenblatt DJ, Divoll M, Harmatz JS, et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982;71:248-52.
47. Yager JY, Seshia SS. Sublingual lorazepam in childhood serial seizures. Am J Dis Child 1988;142:931-2.
48. Korff CM, Nordli DR Jr. Diagnosis and management of nonconvulsive status epilepticus in children. Nat Clin Pract Neurol 2007;3:505-16.
49. Mitchell WG, Conry JA, Crumrine PK, et al. An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, effi cacy, and tolerance. North American Diastat Group. Epilepsia 1999;40:1610-17.
50. Mitchell WG. Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Epilepsia 1996;37(Suppl 1):S74-80.
51. Wilson MT, Macleod S, O'Regan ME. Nasal/buccal midazolam use in the community. Arch Dis Child 2004;89:50-1.
52. Riss J, Cloyd J, Gates J, et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008;118:69-86.
53. Morselli PL, Principi N, Tognoni G, et al. Diazepam elimination in premature and full term infants, and children. J Perinat Med 1973;1:133-41.
54. Ogutu BR, Newton CR, Crawley J, et al. Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions. Br J Clin Pharmacol 2002;53:49-57.
55. McDermott CA, Kowalczyk AL, Schnitzler ER, et al. Pharmacokinetics of lorazepam in critically ill neonates with seizures. J Pediatr 1992;120:479-83.
56. Muchohi SN, Obiero K, Newton CR, et al. Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. Br J Clin Pharmacol 2008;65:12-21.
57. Relling MV, Mulhern RK, Dodge RK, et al. Lorazepam pharmacodynamics and pharmacokinetics in children. J Pediatr 1989;114:641-6.
58. Crom WR, Relling MV, Christensen ML, et al. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther 1991;50:132-40.
59. Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol 1990;39:191-2.
60. de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther 2001;70:525-31.
61. Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol 1989;37:267-72.
62. Rey E, Delaunay L, Pons G, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol 1991;41:355-7.
63. Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 2001;41:1359-69.
64. Walbergh EJ, Wills RJ, Eckhert J. Plasma concentrations of midazolam in children following intranasal administration. Anesthesiology 1991;74:233-5.
65. Chamberlain JM, Altieri MA, Futterman C, et al. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997;13:92-4.
66. Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. Brain Dev 2009;31:744-9.
67. Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2008;3:CD001905.